Abstract
Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.
| Original language | English |
|---|---|
| Journal | Trends in Cardiovascular Medicine |
| Volume | 20 |
| Issue number | 1 |
| Pages (from-to) | 8-12 |
| Number of pages | 5 |
| ISSN | 1050-1738 |
| DOIs | |
| Publication status | Published - 1 Jan 2010 |
Keywords
- Animals
- Blood Pressure
- Cardiovascular Agents
- Glucagon-Like Peptide 1
- Heart Diseases
- Humans
- Myocardial Contraction
- Myocardial Reperfusion Injury
- Signal Transduction
- Treatment Outcome
- Vasodilation
- Ventricular Function, Left